mmissoldtw ←
Francesca Romana Ponziani896 posts
Francesca Romana Ponziani avatar

Francesca Romana Ponziani

@FRPonziani

LiverLover - 4ever Hepatologist

◷ Joined April 2013▧ 78 Photos and videos
Alessandro Vitale avatar
⟳ Francesca Romana Ponziani retweeted
Alessandro Vitale@Vaital73·Apr 3

New letter in Journal of Hepatology (w/ AR & PM) We respond to Mauro et al.’s framework for non-proportional hazards in pivotal HCC trials — and raise 8 methodological concerns: → p-values conflated with clinical relevance → GT test misused as a binary trigger → Internal numerical inconsistencies (CIs excluding null, yet p>0.05) → Retrospective questioning of pre-specified stopping rules → Selective inference in secondary analyses Bottom line: in NPH trials, data maturity, absolute effect size, and clinical applicability must all be evaluated — not just statistical significance. IMbrave050 says it all: MaxCombo p=0.018 at interim → p=0.326 at final analysis. GRADE tools already exist to flag this. Let’s use them. 🔬 @LorenzaRimassa @cabibbo78 @casadei_gardini @Gio_Marchegiani

Treating non-proportional hazards as a yes/no problem risks obscuring clinically relevant time-varying effects. We thus argue for approaches and interpretations grounded in temporal dynamics and clinically meaningful estimands. doi.org/10.1016/j.jhep.2026.…

Post attachment
Alessandro Vitale avatar
⟳ Francesca Romana Ponziani retweeted
Alessandro Vitale@Vaital73·4 Sep 2025

🔄 THE WATERMILL APPROACH 🔄 In the rapidly evolving landscape of hepatocellular carcinoma (HCC) management, the recent article by Edoardo G. Giannini, Jean-François Dufour, and Mario Strazzabosco proposes a compelling conceptual synthesis: the "Watermill Approach" [1]. This elegant metaphor captures the essence of the Multiparametric Therapeutic Hierarchy (MTH) [2] and the Converse Therapeutic Hierarchy (CTH) [3] —two frameworks that challenge the traditional, linear BCLC paradigm. The direction of the water flow reflects the patient's response to initial oncological treatment, influenced by liver function and frailty. As the mill turns, treatment options ascend or descend along a therapeutic gradient—from best supportive care to transplantation. This visual and conceptual model embodies the shift towards adaptive, personalized, and prognosis-modifying strategies in HCC. 📌 Curative intent is no longer a fixed attribute of early-stage disease, but rather a continuum that can be pursued—even in advanced stages—through intelligent sequencing and reassessment. A powerful contribution that aligns with the most advanced trends in multidisciplinary, evidence-based hepatology. 🙏 A special thanks to my friend Edoardo G. Giannini for continuing to drive innovation in the way we think about HCC. [1] authors.elsevier.com/a/1lg9R… [2] pubmed.ncbi.nlm.nih.gov/3741… [3] pubmed.ncbi.nlm.nih.gov/4049…

Post attachment
Francesca Romana Ponziani avatar
Francesca Romana Ponziani@FRPonziani·13 Aug 2025

🔥

FROM RESEARCH TO GUIDELINES 🚀 Proud moment for our team: our study on surgical resection for multinodular BCLC-A #hcc [1] — one of the largest Western matched-cohort analyses — is making waves far beyond its first publication. 🔹 Invited Editorial [2]: praised our methodological rigor, our challenge to restrictive BCLC recommendations, and our role in advancing the Multiparametric Therapeutic Hierarchy. 🔹 Guideline Citations: now included in the latest ESMO 2025 [3] and EASL 2025 [4] HCC guidelines. 🔹 Global Review: featured in CA: A Cancer Journal for Clinicians [5], the world’s top-impact oncology journal, as part of the evolving landscape of surgical management in HCC. This recognition confirms the growing role of evidence-based expansion of surgical indications for carefully selected multinodular HCC patients — a paradigm shift influencing clinical practice worldwide. 🌍 Grateful to my co-authors, collaborators, and the international HCC community for embracing this debate and moving towards more personalized, curative strategies. #livercancer #hcc #oncology #surgery #esmo #easl #medicalresearch #guidelines #evidencebasedmedicine [1]jamanetwork.com/journals/jam… [2]hbsn.amegroups.org/article/v… [3] annalsofoncology.org/article… [4] journal-of-hepatology.eu/art… [5]acsjournals.onlinelibrary.wi…

Post attachmentPost attachment
Alessandro Vitale avatar
⟳ Francesca Romana Ponziani retweeted
Alessandro Vitale@Vaital73·23 Jul 2025

Stop saying “p < 0.05 = significant”. It’s wrong. It’s dangerous. And it’s everywhere. Our latest commentary explains why this myth still prevails in medicine and what we should do instead. 📄 Why is p-Value Controversial? 🔗 doi.org/10.1007/s00270-025-0… With @RovettaAless

Post attachment
Alessandro Vitale avatar
⟳ Francesca Romana Ponziani retweeted
Alessandro Vitale@Vaital73·17 Dec 2024

THE END OF THE STAGE HIERARCHY HCC ERA ... ... towards the MTH approach for patients with HCC ... [272] Vitale A, et al. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol 2023;24(7):e312–e322.

🆕EASL Clinical Practice Guidelines on the management of #hepatocellularcarcinoma❗️ ✅Updated advice for managing patients with #hcc & comprehensive review of pertinent data Full text👉bit.ly/3VKZmcy #cpgs #livertwitter @EASLnews @EASLedu @AleksanderKrag

Post attachment
Francesca Romana Ponziani avatar
Francesca Romana Ponziani@FRPonziani·30 Oct 2024

Our paper selected as Editor’s choice! 📖 a deep insight into 🐛 Akkermansia muciniphila’s role in human diseases 💉 check it out! 🔎 mdpi.com/2072-6643/15/8/1815